73 related articles for article (PubMed ID: 14635084)
21. Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib.
Bombeccari GP; Garagiola U; Pallotti F; Rossi M; Porrini M; Giannì AB; Spadari F
Maxillofac Plast Reconstr Surg; 2017 Dec; 39(1):37. PubMed ID: 29230387
[TBL] [Abstract][Full Text] [Related]
22. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Drilon A; Hu ZI; Lai GGY; Tan DSW
Nat Rev Clin Oncol; 2018 Mar; 15(3):151-167. PubMed ID: 29134959
[TBL] [Abstract][Full Text] [Related]
23. Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
Dai J; Belum VR; Wu S; Sibaud V; Lacouture ME
J Am Acad Dermatol; 2017 Nov; 77(5):902-910.e2. PubMed ID: 28918974
[TBL] [Abstract][Full Text] [Related]
24. Cutaneous complications of molecular targeted therapy used in oncology.
Lupu I; Voiculescu N; Bacalbasa N; Cojocaru I; Vrancian V; Giurcaneanu C
J Med Life; 2016; 9(1):19-25. PubMed ID: 27974909
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine Kinase Inhibitors Regulate OPG through Inhibition of PDGFRβ.
O'Sullivan S; Tay ML; Lin JM; Bava U; Callon K; Cornish J; Naot D; Grey A
PLoS One; 2016; 11(10):e0164727. PubMed ID: 27737004
[TBL] [Abstract][Full Text] [Related]
26. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
27. Delayed Imatinib Treatment for Acute Spinal Cord Injury: Functional Recovery and Serum Biomarkers.
Kjell J; Finn A; Hao J; Wellfelt K; Josephson A; Svensson CI; Wiesenfeld-Hallin Z; Eriksson U; Abrams M; Olson L
J Neurotrauma; 2015 Nov; 32(21):1645-57. PubMed ID: 25914996
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.
Zuo RC; Apolo AB; DiGiovanna JJ; Parnes HL; Keen CM; Nanda S; Dahut WL; Cowen EW
JAMA Dermatol; 2015 Feb; 151(2):170-7. PubMed ID: 25427282
[TBL] [Abstract][Full Text] [Related]
29. KIT is a frequent target for epigenetic silencing in cutaneous melanoma.
Dahl C; Abildgaard C; Riber-Hansen R; Steiniche T; Lade-Keller J; Guldberg P
J Invest Dermatol; 2015 Feb; 135(2):516-524. PubMed ID: 25178104
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate-induced hyperpigmentation of the nose and palate.
Song HS; Kang HY
Ann Dermatol; 2014 Aug; 26(4):532-3. PubMed ID: 25143691
[No Abstract] [Full Text] [Related]
31. Inhibition of c-Kit signaling by diosmetin isolated from Chrysanthemum morifolium.
Lee SJ; Jung TH; Kim H; Jeong D; Choi G; Park WK; Kong JY; Jin MH; Cho H
Arch Pharm Res; 2014 Feb; 37(2):175-85. PubMed ID: 23709168
[TBL] [Abstract][Full Text] [Related]
32. Imatinib-induced Stevens-Johnsons syndrome.
Jha P; Himanshu D; Jain N; Singh AK
BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23349042
[TBL] [Abstract][Full Text] [Related]
33. Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential.
Delbaldo C; Faivre S; Dreyer C; Raymond E
Ther Adv Med Oncol; 2012 Jan; 4(1):9-18. PubMed ID: 22229044
[TBL] [Abstract][Full Text] [Related]
34. Modifying skin pigmentation - approaches through intrinsic biochemistry and exogenous agents.
Brenner M; Hearing VJ
Drug Discov Today Dis Mech; 2008; 5(2):e189-e199. PubMed ID: 19578486
[TBL] [Abstract][Full Text] [Related]
35. Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor.
Kim H; Chang HM; Ryu MH; Kim TW; Sohn HJ; Kim SE; Kang HJ; Park S; Lee JS; Kang YK
J Korean Med Sci; 2005 Jun; 20(3):512-5. PubMed ID: 15953881
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate causes hypopigmentation in the skin.
Leong KW; Lee TC; Goh AS
Cancer; 2004 Jun; 100(11):2486-7; author reply 2487-8. PubMed ID: 15160360
[No Abstract] [Full Text] [Related]
38. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
39. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
